skip to Main Content


The Opportunity

Diabetes are Mediial DeviceBlackhawk Technologies, LLC is exclusively representing HyperMed Imaging Inc. (the“Company”) to monetize its’ assets related to a Medical Device for Tissue Oximetry for Diabetes Care. The offering includes an FDA cleared product used by clinicians and backed by 24 patent families comprising of 62 total assets.

The Company’s pioneering technology has been in service since 2006 and has been validated in third-party published papers that assessed oxyhemoglobin, deoxyhemoglobin, and oxyhemoglobin saturation in superficial tissue for diabetic patients. The Company’s FDA 510(k) cleared product, Hyper View™, quickly determines levels of oxyhemoglobin, deoxyhemoglobin and oxygen saturation in superficial tissue in a small and portable configuration.

The Company seeks a strategic acquirer/licensee with both resources and channels to fully commercialize Company’s IP assets.

The Unmet Medical Need

Most medical exams need quick and accurate determination of superficial tissue oxygenation. For example, complications in diabetes and/or peripheral arterial disease increases risk of lower limb ischemia, chronic wounds, amputation or even death.

• Over 420 million people worldwide (1 in 11 people) have diabetes and the number is increasing rapidly.
• More than 29 million Americans have diabetes. Another 86 million have prediabetes, which is 1 in 3 US adults.
• 8.5 million Americans have peripheral arterial disease and among them nearly 2 million people in the USA are living with limb loss.
• The main causes are vascular disease (54%), including diabetes and peripheral arterial disease.
• Approximately 185,000 amputations occur in the United States each year, costing over $8 billion.
• People with diabetes are at greater risk for severe peripheral arterial disease and are five times more likely to require an amputation.
• It is estimated that a low

Hyperspectral Imaging Benefits

• Non-contact color-coded images depicting concentrations of oxyhemoglobin & deoxyhemoglobin, and oxygen saturation without injectable contrast agents.
• Readings are predictive of wound healing and can be used in screening for peripheral vascular disease.
• Software tools allow clinicians to analyze specified areas within the image to localize ischemic tissue.
• Offers improved patient care with speed, ease of use, and clinical efficiency without injectable contrast or physical contact of the device with the patient.
• Safe, using visible light and spectrometer imaging to quantify light absorption in hemoglobin molecules for rapid analysis without leaving the exam room.

For more details about technology: Click Here

Back To Top